RAAS inhibitors and cardiovascular protection in large scale trials

Thomas G von Lueder, Henry Krum

Research output: Contribution to journalArticleOther

82 Citations (Scopus)

Abstract

Hypertension, coronary artery disease and heart failure affect over half of the adult population in most Western societies, and are prime causes of CV morbidity and mortality. With the ever-increasing worldwide prevalence of CV disease due to ageing and the diabetes pandemic, guideline groups have recognized the importance of achieving cardioprotection in affected individuals as well as in those at risk for future CV events. The renin-angiotensin-aldosterone system (RAAS) is the most important system controlling blood pressure (BP), cardiovascular and renal function in man. As our understanding of the crucial role of RAAS in the pathogenesis of most, if not all, CV disease has expanded over the past decades, so has the development of drugs targeting its individual components. Angiotensin-converting enzyme inhibitors (ACEi), Ang-II receptor blockers (ARB), and mineralcorticoid receptor antagonists (MRA) have been evaluated in large clinical trials for their potential to mediate cardioprotection, singly or in combination. Direct renin inhibitors are currently under scrutiny, as well as novel dual-acting RAAS-blocking agents. Herein, we review the evidence generated from large-scale clinical trials of cardioprotection achieved through RAAS-blockade. ? 2012 Springer Science+Business Media New York.
Original languageEnglish
Pages (from-to)171 - 179
Number of pages9
JournalCardiovascular Drugs and Therapy
Volume27
Issue number2
DOIs
Publication statusPublished - 2013

Cite this